These observations are of importance as they are to our knowledge, the first to study the clinical relevance of MZPL3 in gastric and lung cancers, further supporting the therapeutic potential of the HER3–MPZL3 axis in MET-amplified cancers. This evidence concerns the gene MPZL3 and lung carcinoma.